596 related articles for article (PubMed ID: 21684068)
1. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial).
O'Brien T; Ray E; Singh R; Coker B; Beard R;
Eur Urol; 2011 Oct; 60(4):703-10. PubMed ID: 21684068
[TBL] [Abstract][Full Text] [Related]
2. Re: Tim O'Brien, Eleanor Ray, Rajinder Singh, Bola Coker, Ralph Beard, British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011;60:703-10.
Goel A; Paul S
Eur Urol; 2012 Mar; 61(3):e14; author reply e15. PubMed ID: 22189381
[No Abstract] [Full Text] [Related]
3. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy.
Yafi FA; Novara G; Shariat SF; Gupta A; Matsumoto K; Walton TJ; Fritsche HM; El-Hakim A; Trischler S; Martínez-Salamanca JI; Seitz C; Ficarra V; Zattoni F; Karakiewicz PI; Kassouf W
BJU Int; 2012 Jul; 110(2 Pt 2):E7-13. PubMed ID: 22177329
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
5. Pathological characteristics and clinical course of bladder tumour developing after nephroureterectomy.
Abe T; Shinohara N; Harabayashi T; Sazawa A; Akino T; Ishikawa S; Kubota K; Matsuno Y; Osawa T; Shibata T; Toyoda Y; Shinno Y; Kamota S; Minami K; Sakashita S; Kumagai A; Takada N; Togashi M; Sano H; Mori T; Nonomura K
BJU Int; 2010 Apr; 105(8):1102-6. PubMed ID: 19725822
[TBL] [Abstract][Full Text] [Related]
6. Intravesical recurrence after surgical management of urothelial carcinoma of the upper urinary tract.
Hirano D; Okada Y; Nagane Y; Satoh K; Mochida J; Yamanaka Y; Hirakata H; Yamaguchi K; Kawata N; Takahashi S; Henmi A
Urol Int; 2012; 89(1):71-7. PubMed ID: 22677699
[TBL] [Abstract][Full Text] [Related]
7. Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?
Wu WJ; Ke HL; Yang YH; Li CC; Chou YH; Huang CH
J Urol; 2010 Jan; 183(1):56-61. PubMed ID: 19913833
[TBL] [Abstract][Full Text] [Related]
8. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma.
Li WM; Shen JT; Li CC; Ke HL; Wei YC; Wu WJ; Chou YH; Huang CH
Eur Urol; 2010 Jun; 57(6):963-9. PubMed ID: 20079965
[TBL] [Abstract][Full Text] [Related]
9. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy.
Ouzzane A; Colin P; Xylinas E; Pignot G; Ariane MM; Saint F; Hoarau N; Adam E; Azemar MD; Bensadoun H; Cormier L; Cussenot O; Houlgatte A; Karsenty G; Bruyère F; Maurin C; Nouhaud FX; Phe V; Polguer T; Roumiguié M; Ruffion A; Rouprêt M;
Eur Urol; 2011 Dec; 60(6):1258-65. PubMed ID: 21665356
[TBL] [Abstract][Full Text] [Related]
10. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Böhle A; Van Rhijn BW; Kaasinen E; Palou J; Shariat SF
Eur Urol; 2015 Nov; 68(5):868-79. PubMed ID: 26188393
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy.
Moriarty MA; Uhlman MA; Bing MT; O'Donnell MA; Brown JA; Tracy CR; Deorah S; Nepple KG; Gupta A
BMC Urol; 2015 May; 15():45. PubMed ID: 26018765
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for intravesical recurrence following urothelial carcinoma of the upper urinary tract: no relationship to the mode of surgery.
Koda S; Mita K; Shigeta M; Usui T
Jpn J Clin Oncol; 2007 Apr; 37(4):296-301. PubMed ID: 17513309
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract.
Terakawa T; Miyake H; Muramaki M; Takenaka A; Hara I; Fujisawa M
Urology; 2008 Jan; 71(1):123-7. PubMed ID: 18242379
[TBL] [Abstract][Full Text] [Related]
14. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
16. Laparoscopic radical nephroureterectomy: a multicenter analysis in Japan.
Kamihira O; Hattori R; Yamaguchi A; Kawa G; Ogawa O; Habuchi T; Kawauchi A; Uozumi J; Yokoi S; Tsujihata M; Hasui Y; Miyakoda K; Tada H; Ono Y; Naito S
Eur Urol; 2009 Jun; 55(6):1397-407. PubMed ID: 19299072
[TBL] [Abstract][Full Text] [Related]
17. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma.
Xylinas E; Rink M; Cha EK; Clozel T; Lee RK; Fajkovic H; Comploj E; Novara G; Margulis V; Raman JD; Lotan Y; Kassouf W; Fritsche HM; Weizer A; Martinez-Salamanca JI; Matsumoto K; Zigeuner R; Pycha A; Scherr DS; Seitz C; Walton T; Trinh QD; Karakiewicz PI; Matin S; Montorsi F; Zerbib M; Shariat SF;
Eur Urol; 2014 Jan; 65(1):210-7. PubMed ID: 22579047
[TBL] [Abstract][Full Text] [Related]
18. Expression profile of E-cadherin and N-cadherin in urothelial carcinoma of the upper urinary tract is associated with disease recurrence in patients undergoing nephroureterectomy.
Muramaki M; Miyake H; Terakawa T; Kusuda Y; Fujisawa M
Urology; 2011 Dec; 78(6):1443.e7-12. PubMed ID: 21924460
[TBL] [Abstract][Full Text] [Related]
19. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location.
Zigeuner RE; Hutterer G; Chromecki T; Rehak P; Langner C
BJU Int; 2006 Dec; 98(6):1181-6. PubMed ID: 17125475
[TBL] [Abstract][Full Text] [Related]
20. CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma.
Chung SD; Huang KH; Lai MK; Huang CY; Chen CH; Pu YS; Yu HJ; Chueh SC
Am J Kidney Dis; 2007 Nov; 50(5):743-53. PubMed ID: 17954287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
